Vivek Subbiah, MD

Articles

Key Takeaways and Future Perspectives for In-House Biomarker Testing

February 17th 2025

Panelists discuss how in this discussion the top 3 key points were patient-centric care, enhanced multidisciplinary coordination, and increased access and equity. In the next 3 to 5 years there will be more decentralized testing, potentially more practices participating in genomic profiling, the cost of testing will go down and the turnaround time will be shorter.

Mitigating Socioeconomic Disparities Through Decentralized Testing: Overcoming Barriers to Access and Equity

February 10th 2025

Panelists discuss how decentralizing testing can address socioeconomic disparities by improving access to diagnostics for underserved populations. In-house testing reduces barriers like transportation challenges, lack of insurance, and limited availability of specialized tests, ensuring timely, equitable health care for all communities.

Decentralization of Biomarker Testing: Expanding Access to Targeted Therapies and Clinical Trials in Underserved Populations

February 10th 2025

Panelists discuss how decentralizing biomarker testing improves access to targeted therapies and clinical trials for underserved populations by reducing geographic and systemic barriers, fostering equity in cutting-edge health care.

Impact of In-House Testing on Improved Cancer Care: Timely Decisions and Enhanced Treatment Accuracy

February 3rd 2025

Panelists discuss how in-house laboratory testing has demonstrated significant advantages in patient care through rapid turnaround times and immediate decision-making capabilities. Emergency departments have seen notably improved outcomes when critical tests like cardiac markers and blood gases are performed on-site, enabling faster treatment initiation for acute conditions. For example, rapid troponin testing in-house allows for immediate cardiac intervention decisions, while stat electrolyte panels enable quick medication adjustments for critical patients. Additionally, on-site therapeutic drug monitoring helps clinicians make real-time dosing modifications, which is particularly beneficial for antibiotics and anticoagulation therapy.

Enhancing Multidisciplinary Coordination and Treatment Planning Through In-House Testing

February 3rd 2025

Panelists discuss how in-house testing facilities significantly enhance multidisciplinary coordination by enabling rapid result turnaround and real-time treatment adjustments. This streamlined process facilitates immediate care planning among specialists, leading to faster clinical decisions and reduced wait times. Studies demonstrate that on-site testing correlates with improved patient outcomes through earlier interventions, decreased length of stay, and enhanced treatment monitoring, ultimately supporting more efficient and responsive patient care delivery.

Optimizing In-House Testing: Enhancing Efficiency for Timely Results and Treatment Decisions

January 27th 2025

Panelists discuss how in-house testing significantly reduces turnaround times by eliminating send-out delays and courier dependencies. This enables immediate sample processing, allowing for faster results delivery and prompt clinical decision-making. Health care facilities can optimize workflows through automated systems, clear communication protocols, and standardized testing procedures, minimizing bottlenecks between departments and facilitating quicker diagnosis and treatment initiation.

Implementing In-House Biomarker Testing: Rationale and Key Considerations

January 27th 2025

Panelists discuss how implementing in-house biomarker testing can significantly enhance patient care through faster turnaround times and streamlined decision-making processes. This approach reduces dependence on external laboratories while enabling more immediate clinical interventions. Key implementation considerations include staff expertise, quality control protocols, equipment costs, regulatory compliance, and testing volume to ensure operational efficiency and return on investment

In-House Comprehensive Genomic Profiling: Expert Insight Into Balancing Benefits and Challenges

January 20th 2025

Panelists discuss how in-house comprehensive genomic profiling (CGP) testing offers key benefits like reduced turnaround times, direct control over processes, and immediate access to testing resources. However, significant challenges include substantial initial capital investment, the need for specialized staff recruitment and retention, and ongoing equipment maintenance requirements. Health care facilities must carefully weigh these trade-offs, considering their patient volume, existing infrastructure, and financial capabilities before implementing in-house CGP services.

Centralized vs Decentralized Biomarker Testing: Workflow, Control, and Collaboration Insights

January 20th 2025

Panelists discuss how centralized biomarker testing outsources analysis to specialized laboratories while decentralized testing occurs in-house. In-house testing offers tighter workflow control and closer pathology collaboration but requires more resources, whereas send-out testing leverages external expertise.

When to Choose Narrow Panel Testing Over Comprehensive Testing in Biomarker Analysis

January 16th 2025

Panelists discuss how comprehensive genomic testing may not be practical for well-understood tumors with established treatment pathways. Narrow panel testing is preferred when specific mutations guide therapy (like EGFR in lung cancer) or when time/cost constraints exist.

The Importance of Broad Biomarker Testing: Uncovering Actionable Targets Across Tumor Types

January 16th 2025

Panelists discuss how comprehensive biomarker testing enables detection of actionable mutations across cancer types, informing targeted therapy selection. This broad molecular profiling approach can reveal treatment opportunities regardless of tumor origin.

Key Considerations When Ordering Biomarker Testing

December 24th 2024

Panelists discuss how optimal biomarker testing requires careful balancing of multiple factors. Critical considerations include the turnaround time needed to inform timely treatment decisions, the comprehensiveness of testing panels to identify actionable mutations, and the demonstrated clinical utility of results for guiding therapy selection. Patient-specific factors such as cancer type, stage, prior treatments, and urgency of therapeutic decisions must guide test selection.

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD

October 30th 2024

In this Oncology Unplugged episode, Dr. Chandler Park and Dr. Vivek Subbiah discuss advancements in precision oncology, next-gen sequencing, and tissue-agnostic therapies.

Dr Subbiah on Outcomes With Larotrectinib in TRK Fusion–Positive Solid Tumors

August 20th 2024

Vivek Subbiah, MD, discusses data from the VICTORIA trial which evaluated treatment with larotrectinib in patients with TRK fusion–positive solid tumors.

Outcomes of Larotrectinib Compared With Real-World Data From Non-TRK Inhibitor Therapies in Patients With TRK Fusion Cancer: VICTORIA Study

July 30th 2024

VICTORIA (NCT05192642), is an exact-matching study comparing the outcomes of patients with TRK fusion cancer treated with larotrectinib in 3 clinical trials (NCT02122913, NCT02576431, NCT02637687) to patients treated with non-TRK inhibitor therapies in the real-world (RW) setting.

Dr Subbiah on the Combination of Sapanisertib and Ziv-Aflibercept in Solid Tumors

July 3rd 2024

Vivek Subbiah, MD, discusses the rationale for combining sapanisertib with ziv-aflibercept in recurrent metastatic solid tumors, including kidney cancer.

Clinical Practice Pearls and the Future of SCLC

August 11th 2022

The panel shares clinical pearls for community oncologists treating small cell lung cancer.

Investigational Agents in SCLC in the Second Line Setting and Beyond

August 11th 2022

Taofeek Owonikoko, MD, PhD, highlights investigational agents and ongoing clinical trials in SCLC he looks forward to.

Choosing the Appropriate Treatment in the Second Line Setting in SCLC

August 11th 2022

Experts provide insights on choosing the optimal therapy in patients with small cell lung cancer in the second line and beyond.

Patient Profile 3: A 70-Year-Old Man with SCLC Receiving Chemotherapy in the Second-Line Setting

August 2nd 2022

Dr Jared Weiss presents the profile of a 70-year-old male patient with SCLC who received chemotherapy in the second line setting for discussion to the panel.